See more : Du-Art Film Laboratories, Inc. (DAFL) Income Statement Analysis – Financial Results
Complete financial analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corbus Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kensington Capital Acquisition Corp. V (KCGI-WT) Income Statement Analysis – Financial Results
- madvertise SA (ALMNG.PA) Income Statement Analysis – Financial Results
- Kaishan Group Co., Ltd. (300257.SZ) Income Statement Analysis – Financial Results
- Baying Ecological Holding Group, Inc. (BYIN) Income Statement Analysis – Financial Results
- Realcan Pharmaceutical Group Co., Ltd. (002589.SZ) Income Statement Analysis – Financial Results
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 881.71K | 3.94M | 36.14M | 4.82M | 2.44M | 1.91M | 648.38K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 31.17M | 1.49M | 1.64M | 98.27K | 89.60K | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 0.00 | 0.00 |
| Gross Profit | -31.17M | -1.49M | -757.53K | 3.84M | 36.05M | -43.79M | -23.60M | -13.53M | -5.24M | -1.26M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | -85.92% | 97.50% | 99.75% | -908.11% | -967.09% | -707.60% | -808.21% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.17M | 16.14M | 36.45M | 98.27M | 89.60M | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 210.67K | 575.09 |
| General & Administrative | 13.91M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Selling & Marketing | -641.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.27M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Other Expenses | -30.53M | -48.77K | 11.90M | 13.27M | 4.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.91M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Cost & Expenses | 45.08M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Interest Income | 0.00 | 0.00 | 1.83K | 1.03K | 1.23M | 982.78K | 183.11K | 477.00 | 3.42K | 2.12K | 754.00 | 59.74 |
| Interest Expense | 2.92M | 2.13M | 1.83M | 1.03M | 19.03K | 0.00 | 183.11K | 0.00 | 2.44K | 24.02K | 45.11K | 0.00 |
| Depreciation & Amortization | 640.60K | 1.49M | 1.64M | 1.69M | 1.23M | 493.94K | 255.65K | 87.66K | 43.94K | 10.41K | 754.00 | 824.15 |
| EBITDA | -44.44M | -38.73M | -54.97M | -121.69M | -76.37M | -56.25M | -32.31M | -19.90M | -8.81M | -2.64M | -556.52K | -62.81 |
| EBITDA Ratio | 0.00% | 0.00% | -6,381.74% | -3,101.40% | -212.89% | -1,178.71% | -1,332.72% | -1,040.23% | -1,358.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.08M | -39.84M | -55.99M | -122.81M | -77.10M | -56.75M | -32.56M | -19.99M | -8.85M | -2.65M | -557.28K | -824.15 |
| Operating Income Ratio | 0.00% | 0.00% | -6,350.09% | -3,119.20% | -213.33% | -1,176.78% | -1,334.43% | -1,045.56% | -1,365.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 473.99K | -2.51M | 10.35M | 11.54M | 5.65M | 1.08M | 141.20K | -13.62K | 2.95K | 106.69K | -45.07K | -62.81 |
| Income Before Tax | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Income Before Tax Ratio | 0.00% | 0.00% | -5,176.38% | -2,826.08% | -197.69% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.49M | -87.84K | 35.05K | -2.30M | 1.08M | -396.86K | 13.62K | 2.44K | 24.02K | 44.36K | -62.81 |
| Net Income | -44.60M | -55.83M | -45.55M | -111.30M | -69.15M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Net Income Ratio | 0.00% | 0.00% | -5,166.42% | -2,826.97% | -191.33% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| EPS | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| EPS Diluted | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| Weighted Avg Shares Out | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.00 |
| Weighted Avg Shares Out (Dil) | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.16 |
Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
Hot Marijuana Penny Stocks Under $1 To Watch Ahead Of MORE Act Vote
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports